

HLDA9 ANTIBODY VALIDATION FILE

ANTIBODY INFORMATION

Antibody Name: L307.4

Specificity: CD80

Antibody species: Mouse

Ig Isotype: IgG1 (Kappa)

Immunogen:

Epitope recognized:

Submitter: BD Pharmigen


INFORMATION FOR CONFIRMATION OF SPECIFICITY:

Expression on transfected COS: positive. (Fig. 1A)

Expression on the cell- surface of cell line: positive with Burkitt lymphoma B cell line Namalwa. (Fig. 1B)

Expression on cell- surface of normal cell: positive with tonsil GC B cells (IgD- CD38+). (Fig. 1C)

Figure 1:



Reactivity of CD80 with cell lines

	Cell lines	CD80
EBV-transformed B cells	CESS	++++
Burkitt lymphoma B cell lines	Raji	++++
	Daudi	-
	Namalwa	++++
	Ramos	-
Multiple myeloma	RPMI8226	-
T cell leukemia	Jurkat	-
	HSB2	+++
NK cell leukemia	YT	-
Myeloid leukemia	HL-60	-
	K-562	+++
	U-937	+

Reactivity of CD80 with PBL

Lymphocytes	+
Granulocytes	-
Monocytes	-

INFORMATION PROVIDED BY SUBMITTER

Publications:

Giguère JF, Bounou S, Paquette JS, Madrenas J, Tremblay MJ. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. *J Virol.* 2004 Jun;78(12):6222-32.

Legendre C, Raphael M, Gras G, Lefevre EA, Feuillard J, Dormont D, Richard Y. CD80 expression is decreased in hyperplastic lymph nodes of HIV+ patients. *Int Immunol.* 1998 Dec;10(12):1847-51.

Mauri D, Wyss-Coray T, Gallati H, Pichler WJ. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. *J Immunol.* 1995 Jul 1;155(1):118-27.

Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. *Cancer Res.* 2003 Jul 15;63(14):4067-73.

Patents:

Licensed to a company and which one:

Was it evaluated in a previous workshop? Yes (5TH)